In the limited number of normal tissues in which the folate receptor (FR) type alpha is expressed, the receptor is restricted to apical (luminal) surfaces, where it is inaccessible via the circulation. As a consequence, FR-alpha is regarded as a promising tumor target, particularly in major subtypes of gynecological cancers, for the selective delivery of a broad range of diagnostic and therapeutic agents through the blood stream. Even though a large and growing body of evidence from pre-clinical and clinical studies supports the feasibility of developing such diagnostics/therapies, translating the success obtained in animal models to human cancer is confounded by variability and heterogeneity in the expression levels of FR-alpha in the tumors. We have previously shown that antiestrogens will up-regulate the FR-alpha gene in estrogen receptor (ER)-positive tumors. We now show that the FR-alpha gene can be transcriptionally modulated by the progesterone receptor (PR), the glucocorticoid receptor (GR) and the androgen receptor (AR), greatly expanding the histologic range of FR-alpha+ tumors in which the receptor expression may be optimized for effective targeting. Agonists of PR, GR and AR enhance FR-alpha transcription by apparently distinct mechanisms and in the absence of classical hormone response elements and further, trichostatin A, a histone deacetylase (HDAC) inhibitor, appears to potentiate these effects, overcoming cell context-dependent co-regulator limitations. The actions of PR, GR and AR on the FR-alpha gene will be studied in sufficient mechanistic detail in vitro and in the physiologic milieu of animal tumor xenograft models to establish the biological contexts and clinical conditions in which FR-alpha expression may be controlled through these nuclear receptors.
The specific aims are: (i) Mechanistic studies of nuclear receptor modulation of FR-alpha: Elucidate the individual modes of action (direct vs. indirect) of the nuclear receptors, establish co-regulator requirements/limitations, map the sites of action of PRa, PRb, GR and AR in the FR-alpha promoter, identify and relate the dynamics of the relevant transcription factors, examine the effects of well tolerated HDAC inhibitors and test various synthetic agonists; (ii) Develop and study stable recombinant cell lines that will express the steroid receptors individually and in combination, together with FR-alpha to reflect their in vivo (co)expression patterns in tumors and characterize individual and combined nuclear receptor mediated modulation of FR-alpha in these cells in vitro and mechanisms of potential cross-talk; (iii) Test the effects of the appropriate steroid receptor agonists and antagonists and HDAC inhibitors in animal tumor xenograft models using representative model cell lines developed in Aim ii and FR-targeted imaging agents. It is anticipated that the proposed studies will systematically establish a foundation for clinical trials of this concept of manipulating tumor tissues to enhance the sensitivity of whole body imaging and the therapeutic efficacy of FR-targeted agents.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-ET-2 (04))
Program Officer
Jhappan, Chamelli
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Toledo
Schools of Medicine
United States
Zip Code
Rosati, Rayna; Polin, Lisa; Ducker, Charles et al. (2018) Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer. Clin Cancer Res 24:6509-6522
Patki, Mugdha; Gadgeel, Shirish; Huang, Yanfang et al. (2014) Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed. J Thorac Oncol 9:519-26
Gonit, Mesfin; Zhang, Juan; Salazar, Marcela d'Alincourt et al. (2011) Hormone depletion-insensitivity of prostate cancer cells is supported by the AR without binding to classical response elements. Mol Endocrinol 25:621-34
Zhang, J; Gonit, M; Salazar, M D et al. (2010) C/EBPalpha redirects androgen receptor signaling through a unique bimodal interaction. Oncogene 29:723-38
Sivakumaran, Suneethi; Zhang, Juan; Kelley, Karen M M et al. (2010) Androgen activation of the folate receptor ? gene through partial tethering of the androgen receptor by C/EBP?. J Steroid Biochem Mol Biol 122:333-40
Zhang, Juan; Wilkinson, John Erby; Gonit, Mesfin et al. (2008) Expression and sub-cellular localization of the CCAAT/enhancer binding protein alpha in relation to postnatal development and malignancy of the prostate. Prostate 68:1206-14
Hao, H; d'Alincourt-Salazar, M; Kelley, K M M et al. (2007) Estrogen-induced and TAFII30-mediated gene repression by direct recruitment of the estrogen receptor and co-repressors to the core promoter and its reversal by tamoxifen. Oncogene 26:7872-84
Shatnawi, Aymen; Tran, Thuyet; Ratnam, Manohar (2007) R5020 and RU486 act as progesterone receptor agonists to enhance Sp1/Sp4-dependent gene transcription by an indirect mechanism. Mol Endocrinol 21:635-50
Salazar, Marcela D'Alincourt; Ratnam, Manohar (2007) The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 26:141-52
Elnakat, Hala; Ratnam, Manohar (2006) Role of folate receptor genes in reproduction and related cancers. Front Biosci 11:506-19

Showing the most recent 10 out of 12 publications